Psychiatric diagnosis and clinical trial completion rates: Analysis of the FDA SBA reports

Neuropsychopharmacology

Volumn 32, Issue 11, 2007, Pages 2422-2430

  Khan, Arif ^a,b   Schwartz, Kelly ^a   Redding, Nick ^a   Kolts, Russell L ^c   Brown, Walter A ^d,e  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c EASTERN WASHINGTON UNIVERSITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Completion rates; Placebo; Psychiatric diagnosis; Psychopharmacology; Psychotropics

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; OLANZAPINE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; VENLAFAXINE; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 35348894443     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301361     Document Type: Article

References (49)

1. Andersch S, Rosenberg NK, Kullingsjö H, Ottosson J-O, Bech P, Bruun-Hansen J et al (1991). Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand 365: 18-27.
2. Anderson IM, Tomenson BM (1995). Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310: 1433-1438.
3. Arvanitis LA, Miller BG, The Seroquel Trial 13 Study Group (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-246.
4. Baekeland F, Lundwall L (1975). Dropping out of treatment: a critical review. Psychol Bull 82: 738-783.
5. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP (1998). Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155: 36-42.
6. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW et al (1993). A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25-40.
7. Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC (1992). Paroxetine vs placebo: a double-blind comparison in depressed patients. J Clin Psychiatry 53: 434-438.
8. Cohn JB, Wilcox C (1985). A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 46: 26-31.
9. Dunbar GC, Claghorn JL, Kiev A, Rickels K, Smith WT (1993). A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand 87: 302-305.
10. Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J et al (1991). A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 159: 394-398.
11. Enkelmann R (1991). Alprazolam vs buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 105: 428-432.
12. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petri WM et al (1995). Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Pyschiatry 38: 592-602.
13. Feighner JP, Boyer WF (1989). Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scan 350: 125-129.
14. Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S et al (1994). A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 55: 234-241.
15. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. JAMA 283: 3082-3088.
16. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L et al (1995). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52: 289-295.
17. Hamilton SH, Revicki DA, Genduso LA, Beasley Jr CM (1998). Olanzapine vs placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 18: 41-49.
18. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL et al (2002). Efficacy and safety of aripiprazole and haloperidol vs placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763-771.
19. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW (2005). Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drug. Arch Gen Psychiatry 62: 1305-1312.
20. Khan A, Detke M, Khan S, Mallenkrodt C (2003a). Placebo response and antidepressant clinical trial outcomes. J Nerv Mental Dis 19: 211-218.
21. Khan A, Khan SR, Walens G, Kolts R, Giller EL (2003b). Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration Summary Basis of Approval reports. Neuropsychopharmacology 28: 552-557.
22. Khan A, Kolts RL, Rapaport MH, Krishnan KRR, Brodhead AE, Brown WA (2005). Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med 35: 743-749.
23. Khan A, Kolts RL, Thase ME, Krishnan KRR, Brown W (2004). Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 161: 2045-2049.
24. Khan A, Schwartz K (2005). Design features that affect psychopharmacology trials. Lett Drug Des Discovery 2: 546-550.
25. Kiev A (1992). A double-blind, placebo-controlled study of paroxetine in depressed outpatients. J Clin Psychiatry 53(Suppl 2): 27-29.
26. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D (2002). Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159: 88-95.
27. Labelle A, Boulay LJ, Lapierre YD (1999). Retention rates in placebo- and nonplacebo- controlled clinical trials of schizophrenia. Can J Psychiaty 44: 887-892.
28. Lecrubier Y, Bakker A, Dunbar G, Judge R, The Collaborative Paroxetine Panic Study Investigators (1997). A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Pscyhiatr Scand 95: 145-152.
29. Lecrubier Y, Judge R, the Collaborative Paroxetine Panic Study Investigators (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 95: 153-160.
30. Leon AC (2000). Placebo protects subjects from nonresponse: a paradox of power. Arch Gen Psychiatry 57: 329-330.
31. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 353: 1209-1221.
32. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD (2002). A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63: 66-74.
33. Lineberry CG, Johnston JA, Raymond RN, Samara B, Feighner JP, Harto NE et al (1990). A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 51: 194-199.
34. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J et al (1998). Sertraline in the treatment of panic disorder. Br J Psychiatry 173: 54-60.
35. Lydiard RB, Stahl SM, Hertzman M, Harrison WM (1997). A double-blind, placebo-controlled study comparing the effects of sertraline vs amitriptyline in the treatment of major depression. J Clin Psychiatry 58: 484-491.
36. Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-trial study group (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161: 975-984.
37. Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF (1995). A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 56(Suppl 6): 30-36.
38. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, et al, The Lilly European OCD Study Group (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Euro Neuropsychopharmacol 3: 143-152.
39. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D (2005). Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 25: 660-667.
40. Pelagotti F, Santarlasci B, Vacca F, Trippoli S, Messori A (2004). Dropout rates with olanzapine or risperidone: a multi-centre observational study. Eur J Clin Pharmacol 59: 905-909.
41. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998). Sertraline in the treatment of panic disorder. Arch Gen Psychiatry 55: 1010-1016.
42. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E et al (2003). Aripiprazole, and antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60: 681-690.
43. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY (2001). Sertraline treatment of panic disorder: results of a longterm study. Acta Psychiatr Scand 104: 289-298.
44. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD et al (1990). Antidepressant efficacy of sertraline: a double blind, placebo-and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Pyschiatry 51(Suppl 12B): 18-27.
45. Rickels K, Amsterdam J, Clary C, Gox I, Schweizer E, Weise C (1992). The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. J Clin Psychiatry 53(Suppl 2): 30-32.
46. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000). Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157: 968-974.
47. Shrivastava RK, Shrivastava SHP, Overweg N, Blumhardt CL (1992). A double-blind comparison of paroxetine, imipramine, and placebo in major depression. J Clin Psychiatry 53(Suppl 2): 48-51.
48. Smith WT, Glaudin V (1992). A placebo-controlled trial of paroxetine in the treatment of major depression. J Clin Psychiatry 53(Suppl 2): 36-39.
49. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998). Paroxetine treatment of generalized social phobia (social anxiety disorder). JAMA 280: 708-713.